Infectious Epstein-Barr virus lacking major glycoprotein BLLF1 (gp350/220) demonstrates the existence of additional viral ligands

Journal of Virology

Volumn 74, Issue 21, 2000, Pages 10142-10152

  Janz, A ^a   Oezel, M ^a   Kurzeder, C ^a   Mautner, J ^a   Pich, D ^a   Kost, M ^a   Hammerschmidt, W ^a   Delecluse, H J ^a  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CELL RECEPTOR; COMPLEMENT COMPONENT C3D RECEPTOR; LIGAND; VIRUS GLYCOPROTEIN;

ANIMAL CELL; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; EPITHELIUM CELL; EPSTEIN BARR VIRUS; GENE DELETION; GENETIC CODE; HUMAN; HUMAN CELL; LYMPHOID CELL; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; TARGET CELL; VIRUS INFECTION; VIRUS MUTANT; VIRUS RECOMBINANT;

B-LYMPHOCYTES; CELL LINE; CELL TRANSFORMATION, VIRAL; EPITHELIAL CELLS; GENE DELETION; HERPESVIRUS 4, HUMAN; HUMAN; LIGANDS; RECEPTORS, COMPLEMENT 3D; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; VIRAL MATRIX PROTEINS; VIRION; VIRULENCE;

EID: 0033775926     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.74.21.10142-10152.2000     Document Type: Article

References (51)

1. Human B cell variants immunoselected against a single Ia antigen subset have lost expression of several Ia antigen subsets
2. Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line
3. Receptor-binding properties of a soluble form of human cytomegalovirus glycoprotein B
4. Structural requirements for C3d,g/Epstein-Barr virus receptor (CR2/CD21) ligand binding, internalization, and viral infection
5. Requirement for cell-to-cell contact in Epstein-Barr virus infection of nasopharyngeal carcinoma cells and keratinocytes
6. Gene disruption in Escherichia coli: TcR and KmR cassettes with the option of Flp-catalyzed excision of the antibiotic-resistance determinant
7. Initiation of human cytomegalovirus infection requires initial interaction with cell surface heparan sulfate
8. Propagation and recovery of intact, infectious Epstein-Barr virus from prokaryotic to human cells
9. Superinfection by Epstein-Barr virus of a subset of Raji cells is independent of HLA class-II antigens
10. CD21-dependent infection of an epithelial cell line, 293, by Epstein-Barr virus
11. Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2
12. Entry of alphaherpesviruses mediated by poliovirus receptor-related protein 1 and poliovirus receptor
13. Characteristics of a human cell line transformed by DNA from human adenovirus type 5
14. Sequence complexity of circular Epstein-Barr virus DNA in transformed cells
15. Identification and characterization of oriLyt, a lyric origin of DNA replication of Epstein-Barr virus
16. Studies on transformation of Escherichia coli with plasmids
17. Cell-to-cell contact as an efficient mode of Epstein-Barr virus infection of diverse human epithelial cells
18. The basis of the tumorigenicity of BHK 21 cells
19. A human cytomegalovirus glycoprotein complex designated gC-II is a major heparin-binding component of the envelope
20. An enhancer factor defect in a mutant Burkitt lymphoma cell line
21. Heparan sulfate proteoglycan binding by herpes simplex virus type 1 glycoproteins B and C, which differ in their contributions to virus attachment, penetration, and cell-to-cell spread
22. p53 Mutations in human immortalized epithelial cell lines
23. Epstein-Barr virus uses HLA class II as a cofactor for infection of B lymphocytes
24. The Epstein-Barr virus (EBV) BZLF2 gene product associates with the gH and gL homologs of EBV and carries an epitope critical to infection of B cells but not of epithelial cells
25. Epstein-Barr virus: Biology, pathogenesis, and medical aspects
26. A monoclonal antibody to glyco-protein gp85 inhibits fusion but not attachment of Epstein-Barr virus
27. Epstein-Barr virus gH is essential for penetration of B cells but also plays a role in attachment of virus to epithelial cells
28. Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family
29. Identification of an epitope in the major envelope protein of Epstein-Barr virus that mediates viral binding to the B lymphocyte EBV receptor (CR2)
30. Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV/C3d receptor of B cells: Sequence homology of gp350 and C3 complement fragment C3d
31. Identification and characterization of the Epstein-Barr virus receptor on human B lymphocytes and its relationship to the C3d complement receptor (CR2)
32. The organization of the envelope projections on the surface of HIV
33. Direct interaction between human cytomegalovirus glycoprotein B and cellular annexin II
34. Characterization of C3dg binding to a recess formed between short consensus repeats 1 and 2 of complement receptor type 2 (CR2; CD21)
35. Cytology of Burkitt's tumour (African lymphoma)
36. Biological characteristics and viral susceptibility of an African green monkey kidney cell line (Vero)
37. Epstein-Barr virus in nasopharyngeal and salivary gland carcinomas of Greenland Eskimoes
38. Epstein-Barr virus-associated gastric adenocarcinoma
39. Replication of Epstein-Barr virus in human epithelial cells infected in vitro
40. Entry of alphaherpesviruses into cells
41. The extracellular domain of the Epstein-Barr virus BZLF2 protein binds the HLA-DR beta chain and inhibits antigen presentation
42. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome)
43. Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis
44. Soluble gp350/220 and deletion mutant glycoproteins block Epstein-Barr virus adsorption to lymphocytes
45. Expression of C3d receptors during human B cell differentiation: Immunofluorescence analysis with the HB-5 monoclonal antibody
46. Identification and isolation of the main component (gp350-gp220) of Epstein-Barr virus responsible for generating neutralizing antibodies in vivo
47. Epstein-Barr virus glycoprotein gp85 associates with the BKRF2 gene product and is incompletely processed as a recombinant protein
48. Epstein-Barr virus infection of human gastric carcinoma cells: Implication of the existence of a new virus receptor different from CD21
49. Epstein-Barr virus receptors on human pharyngeal epithelia
50. Rapid proliferation of B cells from adenoids in response to Epstein-Barr virus infection
51. EB-virus DNA in biopsies of Burkitt tumors and anaplastic carcinomas of the nasopharynx